Tyroserleutide (YSL)
Names
[ CAS No. ]:
138168-48-6
[ Name ]:
Tyroserleutide (YSL)
[Synonym ]:
L-Tyrosyl-L-seryl-L-leucine
L-Leucine, L-tyrosyl-L-seryl-
Biological Activity
[Description]:
Tyroserleutide (YSL), isolated from the degradation products of porcine spleen[1], is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo[2].
[Related Catalog]:
[Target]
Antitumor tripeptide[1][2]
[In Vitro]
Tyroserleutide (YSL) exhibits immuno-modulating effects, such as enhancing concanavalin (ConA) induced proliferation of mouse spleen lymphocytes, phagocytosis of mouse peritoneal macrophages, and the activity of natural killer (NK) cells[1]. Tyroserleutide (YSL), an immunologically therapeutic tripeptide, can promote hepatocarcinoma cell (H22) apoptosis through downregulating Bcl-2 and cyclin D1 expression[2]. Tyroserleutide is an ideal choice for inducing apoptosis of liver tumor cells[2]. Tyroserleutide inhibits tumor growth and does not cause severe toxicities in the major organs. Tyroserleutide can inhibit tumor cell migration[2].
[In Vivo]
Tyroserleutide (10-80 μg/kg; injection (i.p.) one time every day until mice are dead) displays obvious anti-tumor activity. Tyroserleutide significantly prolongs the survival time of the murine H22 implanted mice[1]. Animal Model: Female Kun-Ming mice (18-22 g, 6 week old) with H22 tumor model[1] Dosage: 10, 20, 40, and 80 μg/kg Administration: Injection (i.p.) one time every day until mice were dead. Result: Survival times are 25.53±14.14, 25.82±14.29, 30.47±17.89, 35.06±20.90 days for 10, 20, 40, and 80 μg/kg, respectively.
[References]
Chemical & Physical Properties
[ Density]:
1.3±0.1 g/cm3
[ Boiling Point ]:
763.8±60.0 °C at 760 mmHg
[ Molecular Formula ]:
C18H27N3O6
[ Molecular Weight ]:
381.423
[ Flash Point ]:
415.7±32.9 °C
[ Exact Mass ]:
381.189972
[ LogP ]:
0.89
[ Vapour Pressure ]:
0.0±2.7 mmHg at 25°C
[ Index of Refraction ]:
1.577